FrancophonIA/ELRC3.0 huggingface dataset:
English: Genotypic analysis showed mutations in the HIV-1 RT gene Y181C and/or V106A depending upon the virus strain and cell line employed.
Maltese: Analiżi ġenotipika wriet mutazzjonijiet fil-ġene RT Y181C u/jew V106A ta' HIV-1 skont ir-razza tal-virus u r-razza ta' ċelluli użati.
English: Nevirapine exhibited additive to synergistic anti-HIV-1 activity in combination with the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, saquinavir and tipranavir, and the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir and zidovudine.
Maltese: l-inibituri ta' protease, amprenavir, atazanavir, indinavir, lopinavir, saquinavir u tipranavir, u l-NRTIs abacavir, didanosine emtricitabine, lamivudine, stavudine, tenofovir u zidovudine.
English: Clinical hepatitis reported as clinical adverse event occurred in 10 (2.6%) and 2 (0.5%) patients in the nevirapine twice daily and efavirenz groups respectively.
Maltese: Epatite klinika rrapportata bħala każ avvers kliniku seħħet f'10 (2.6%) u 2 (0.5%) pazjenti fil-gruppi ta' nevirapine li ngħata darbtejn kuljum u ta' efavirenz rispettivament.
English: An increase in the dose of lopinavir/ritonavir to 533/133 mg (4 capsules) or 500/125 mg (5 tablets with 100/25 mg each) twice daily with food is recommended in combination with Nevirapine Teva.
Maltese: Żieda fid-doża ta' lopinavir/ritonavir għal 533/133 mg (4 kapsuli) jew 500/125 mg (5 pilloli b'100/25 mg kull darba) darbtejn kuljum mal-ikel hi rrakkomandata flimkien ma' Nevirapine Teva.
English: ANTITHROMBOTICS
Maltese: ANTIBIJOTIĊI
English: The 14-day “lead-in” period has been shown to lower the risk of skin rash.
Maltese: Il-perijodu “inizjali” ta' 14-il jum intwera li jnaqqas ir-riskju ta' raxx fuq il-ġilda.
English: Very common rash (12.5 %)
Maltese: Disturbi tal-ġilda u tat-tessuti ta' taħt il-ġilda Komuni ħafna raxx (12.5%)
English: Nevirapine Teva 200 mg tablets
Maltese: Nevirapine Teva 200 mg pilloli
English: Data reported in the literature from 20 HIV-infected patients suggest a steady state Cmax of 5.74 μg/ml (5.00-7.44) and Cmin of 3.73 μg/ml (3.20-5.08) with an AUC of 109.0 h*μg/ml (96.0-143.5) in patients taking 200 mg of nevirapine bid.
Maltese: Skont dejta ppubblikata fuq 20 pazjent infettati b'HIV, l-valur Cmax ta' nevirapine waqt ekwilibriju kien ta' 5.74 µg/ml (5.00-7.44) u Cmin kien ta' 3.73 µg/ml (3.20-5.08), b'AUC ta'
English: Pharmacokinetic data on 33 patients (age range 0.77 - 13.7 years) in the intensive sampling group demonstrated that clearance of nevirapine increased with increasing age in a manner consistent with increasing body surface area.
Maltese: Dejta farmakokinetika fuq 33 pazjent (età mifruxa bejn 0.77 - 13.7 sena) fil-grupp li ttieħdu kampjuni intensivi wriet li r-rata ta' eliminazzjoni ta' nevirapine żdiedet meta l-età żdiedet b'mod konsistenti ma' żieda fl-erja superfiċjali tal-ġisem.
English: The frequency category was estimated from a statistical calculation based on the total number of patients exposed to nevirapine in randomised controlled clinical studies (n= 2,718).
Maltese: Il-kategorija ta' frekwenza ġiet stmata mill-kalkulazzjoni statistika bbażata fuq in-numru totali ta' pazjenti esposti għal nevirapine fi studji kliniċi kkontrollati li fihom il-parteċipanti ntgħażlu b'mod każwali (n=2,718).
English: Nevirapine Teva 200 mg tablets nevirapine
Maltese: Nevirapine Teva 200 mg pilloli nevirapine
English: Renal dysfunction: The single-dose pharmacokinetics of nevirapine has been compared in 23 patients with either mild (50 ≤ CLcr < 80 ml/min), moderate (30 ≤ CLcr < 50 ml/min) or severe renal dysfunction (CLcr < 30 ml/min), renal impairment or end-stage renal disease (ESRD) requiring dialysis, and 8 patients with normal renal function (CLcr > 80 ml/min).
Maltese: Il-farmakokinetika ta' doża waħda ġiet imqabbla fi 23 pazjent li wħud kellhom indeboliment fil-kliewi ħafif (50 ≤ CLcr < 80 ml/min), moderat (30 ≤ CLcr < 50 ml/min) jew qawwi (CLcr < 30 ml/min), jew f'pazjenti morda serjament bil-kliewi li ħtieġu dijaliżi, 8 pazjenti kellhom kliewi normali (CLcr > 80 ml/min).
English: Clarithromycin Cmin ↓ 0.44 (0.30Clarithromycin Cmax ↓ 0.77 (0.69
Maltese: Clarithromycin AUC ↓ 0.69 (0.62Clarithromycin Cmin ↓ 0.44 (0.30Clarithromycin Cmax ↓ 0.
English: Nevirapine had no antiviral activity in cell culture against group O HIV-1 isolates or HIV-2 isolates.
Maltese: Nevirapine ma kellux attività antivirali fil-kultura ta' ċelluli kontra kampjuni HIV-1 jew HIV-2 minn grupp O.
English: An increased risk was observed in men with detectable HIV-1 RNA in plasma and CD4 counts > 400 cells/mm3 (6.3 % versus 1.2 % for men with CD4 counts < 400 cells/mm3).
Maltese: Riskju akbar kien osservat ukoll f'irġiel li kellhom għadd osservat ta' HIV-1 RNA fil-plażma u ta' ċelluli CD4 > 400 ċelluli/mm3 (6.3% kontra 1.2% għall-irġiel b'għadd ta' CD4 < 400 ċellula/mm3).
English: Because the clarithromycin active metabolite has reduced activity against Mycobacterium aviumintracellulare complex overall activity against the pathogen may be altered.
Maltese: clarithromycin għandu attività mnaqqsa kontra l-kumpless intraċellulari ta' Mycobacterium avium, l-attività globali kontra l-patoġenu tista' tinbidel.
English: The simultaneous use of nevirapine (400 mg) plus efavirenz (800 mg) was associated with the highest frequency of clinical adverse events and with the highest rate of treatment failure (53.1%).
Maltese: L-użu f'daqqa ta' nevirapine (400 mg) flimkien ma' efavirenz (800 mg) kien assoċjat mal-ogħla frekwenza ta' każijiet avversi kliniċi u mal-ogħla rata ta' falliment fil-kura (53.1%).
English: 2 years
Maltese: 3 snin
English: Hypersensitivity (anaphylactic reaction, angioedema and urticaria) have been reported.
Maltese: Ġew irrapportati reazzjonijiet allerġiċi (anafilassi, anġoedema u urtikarja).
English: Absolute bioavailability in 12 healthy adults following single-dose administration was 93 ± 9% (mean SD) for a 50 mg tablet and 91 ± 8 % for an oral solution.
Maltese: Il-bijodisponibilità assoluta fi 12-il adult b'saħħithom, wara li ngħataw doża waħda kienet ta' 93 ± 9% (SD medja) għal pillola ta' 50 mg u ta' 91 ± 8% għal soluzzjoni orali.
English: Itraconazole Cmin ↓ 0.13 Itraconazole Cmax ↓ 0.62
Maltese: Itraconazole AUC ↓ 0.39 Itraconazole Cmin ↓ 0.13
English: Furthermore, combining the following compounds with Nevirapine Teva is not recommended: efavirenz, ketoconazole, delavirdine, etravirine, rilpivirine, elvitegravir (in combination with cobicistat), atazanavir (in combination with ritonavir), boceprevir; fosamprenavir (if not co-administered with low dose ritonavir) (see section 4.5).
Maltese: Flimkien ma' dan, li tikkombina l-komposti li ġejjin ma' Viramune mhuwiex rakkomandat: efavirenz, ketoconazole, delavirdine, etravirine, rilpivirine, elvitegravir (flimkien ma' cobicistat), atazanavir (flimkien ma' ritonavir), boceprevir; fosamprenavir (jekk ma jingħatax flimkien ma' doża baxxa ta' ritonavir) (ara sezzjoni 4.5).
English: Nevirapine belongs to a class of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Maltese: mediċini li jaħdmu kontra l-HIV imsejħa non-nucleoside reverse transcriptase (NNRTIs).
English: Nevirapine is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3).
Maltese: Nevirapine huwa kontra-indikat f'pazjenti li għandhom indeboliment qawwi fil-fwied (Child-Pugh C, ara sezzjoni 4.3).
English: The most frequently observed laboratory test abnormalities are elevations in liver function tests (LFTs), including ALAT, ASAT, GGT, total bilirubin and alkaline phosphatase.
Maltese: L-aktar anormalitajiet komuni li jirriżultaw minn testijiet tal-laboratorju huma żjidiet fil-fatturi mkejla permezz ta' testijiet tal-funzjoni tal-fwied (LFTs), li jinkludu ALAT, ASAT, GGT, bilirubin totali u alkaline phosphatase.
English: 1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to nevirapine 400 mg once daily, nevirapine 200 mg twice daily, efavirenz 600 mg once daily, or nevirapine (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
Maltese: tal-HIV-1 fil-plażma fil-linja bażi ġew assenjati nevirapine 400 mg darba kuljum, nevirapine 200 mg darbtejn kuljum, efivirenz 600 mg darba kuljum, jew Nevirapine Teva (400 mg) u efivarenz (800 mg)
English: Hepatic dysfunction: A steady state study comparing 46 patients with mild (n=17: Ishak Score 1-2), moderate (n=20; Ishak Score 3-4), or severe (n=9; Ishak Score 5-6, Child-Pugh A in 8 pts., for 1 Child-Pugh score not applicable) liver fibrosis as a measure of hepatic impairment was conducted.
Maltese: Sar studju ta' stadju fiss li qabbel 46 pazjent ma' fibrosi tal fwied ħafifa (n=17: Punteġġ Ishak 1-2), moderata (n=20; Punteġġ Ishak 3-4), jew qawwija (n=9; Punteġġ Ishak 5-6, Child-Pugh A fi 8 pti., mhux applikabbli għal punteġġ Child
English: Dosing of nevirapine at 150 mg/m2 BID (after a two-week lead in at 150 mg/m2 QD) produced geometric mean or mean trough nevirapine concentrations between 4-6 μg/ml (as targeted from adult data).
Maltese: Dożi ta' nevirapine ta' 150 mg/m2 BID (wara ġimagħtejn jingħataw b'150 mg/m2 QD) rriżultaw f'medja ġeometrika jew f'konċentrazzjonijiet minimi medji ta' nevirapine ta' bejn 4-6 µg/ml (kif immirata minn dejta fuq adulti).
English: Data concerning the pharmacokinetics of nevirapine have been derived from two major sources: a 48 week paediatric study in South Africa (BI 1100.1368) involving 123 HIV-1 positive, antiretroviral naïve patients aged 3 months to 16 years; and a consolidated analysis of five Paediatric AIDS Clinical Trials Group (PACTG) protocols comprising 495 patients aged 14 days to 19 years.
Maltese: 1368) li saret fl-Afrika t'Isfel li tinvolvi 123 HIV-1 pazjenti pożittivi bejn l-etajiet ta' 3 xhur u 16-il sena, li ma kienux jafu li qed jieħdu mediċina antiretrovirali; u analiżi konsolidata ta' ħames protokolli tal-Paediatric AIDS Clinical Trials Group (PACTG) li kellhom 495 pazjent bejn l-etajiet ta' 14-il jum u 19-il sena.
English: Absorption: Nevirapine is readily absorbed (> 90 %) after oral administration in healthy volunteers and in adults with HIV-1 infection.
Maltese: Nevirapine ġie assorbit mill-ewwel (>90%) wara li ngħata mill-ħalq f'voluntieri b'saħħithom u adulti infettati b'HIV-1.
English: Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children of any age (see section 4.2).
Maltese: Nevirapine Teva huwa maħsub biex jingħata flimkien ma' prodotti mediċinali anti-retrovirali oħra għall-kura ta' adulti, adoloxxenti u tfal ta' kwalunkwe età infettati bl-HIV-1 (ara sezzjoni 4.4).
English: Rifabutin Cmin ↔ 1.07 (0.84-1.37) Rifabutin Cmax ↑ 1.28 (1.09-1.51)
Maltese: Rifabutin AUC ↑ 1.17 (0.98-1.40) Rifabutin Cmin ↔ 1.07 (0.84-1.37) Rifabutin Cmax ↑ 1.28 (1.09-1.51)
English: Darunavir Cmin ↔ 1.02 (0.79-1.32) Darunavir Cmax ↑ 1.40 (1.14-1.73)
Maltese: Darunavir AUC ↑ 1.24 (0.97-1.57) Darunavir Cmin ↔ 1.02 (0.79-1.32) Darunavir Cmax ↑ 1.40 (1.14-1.73)
English: Both, the primary (p = 0.92) and secondary endpoints showed no statistically significant differences between efavirenz and nevirapine 200 mg twice daily.
Maltese: Kemm il-punt ta' riferenza prinċipali (p = 0.92) u dak sekondarju ma wrew ebda differenza statistikament sinifikanti bejn efavirenz u nevirapine 200 mg li ingħata darbtejn kuljum.
English: Eastbourne, East Sussex, BN22 9AG United Kingdom
Maltese: TEVA UK Ltd Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG Ir-Renju Unit
English: Significantly fewer patients in the abacavir group (9 patients, or 6%) than in the nevirapine group (26 patients, or 17%) or the efavirenz group (27 patients, or 17%) discontinued the medicinal product because of adverse events.
Maltese: Kien hemm sinifikament inqas pazjenti fil-grupp ta' abacavir (9 pazjenti, jew 6%) milli filgrupp ta' nevirapine (26 pazjent, jew 17%) jew fil-grupp ta' efavirenz (27 pazjent, jew 17%) li ġew mwaqqfa milli jkomplu jieħdu l-prodott mediċinali minħabba każijiet avversi.
English: Amprenavir Cmin ↓ 0.65 (0.49-0.85) Amprenavir Cmax ↓ 0.75 (0.63-0.89)
Maltese: Amprenavir AUC ↓ 0.67 (0.55-0.80) Amprenavir Cmin ↓ 0.65 (0.49-0.85) Amprenavir Cmax ↓ 0.75 (0.63-0.89)
English: HIV-1 isolates with reduced susceptibility (100-250-fold) to nevirapine emerge in cell culture.
Maltese: Kampjuni ta' HIV-1 b'suxxetibilità mnaqqsa (100-250 darba) għal nevirapine tfaċċaw fil-kultura ta'
English: Cartons containing 14 tablets (Calendar Pack).
Maltese: Il-kaxxa fiha 14-il pillola (Pakkett bil-kalendarju).
English: Isolated cases of Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition syndrome have been reported in this population.
Maltese: F'din il-popolazzjoni ġew irrapportati każijiet iżolati ta' sindromu ta' Stevens-Johnson jew sindromu bejn Stevens-Johnson u nekroliżi epidermali tossika.
English: Nevirapine is a non-competitive inhibitor of the HIV-1 reverse transcriptase, but it does not have a biologically significant inhibitory effect on the HIV-2 reverse transcriptase or on eukaryotic DNA polymerases α, β, γ, or δ.
Maltese: Nevirapine huwa impeditur mhux kompettitiv tal-HIV reverse transcriptase, imma m'għandux effett inibitorju bijoloġikament sinifikanti fuq HIV-2 reverse transcriptase jew fuq DNA polymerases tal-ewkarjote α, β, γ, jew δ.
English: - or have a body surface area above 1.25 square metres.
Maltese: - jiżnu 50 kg jew aktar - li għandhom erja superfiċjali 'l fuq minn 1.25 metri kwadri.
English: Cross-resistance between nevirapine and either HIV protease inhibitors, HIV integrase inhibitors or HIV entry inhibitors is unlikely because the enzyme targets involved are different.
Maltese: Reżistenza inkroċjata bejn nevirapine u jew impedituri tal-protease tal-HIV, impedituri tal-integrase tal-HIV, jew impedituri tad-dħul tal-HIV mhix probabbli peress li l-miri enzimatiċi involuti huma differenti.
English: Nevirapine Teva contains lactose
Maltese: Nevirapine Teva fih il-lactose
English: Ελλάδα Teva Ελλάς Α.Ε.
Maltese: Il-ġilda u t-tessuti ta' taħt il-ġilda
English: Nevirapine Teva belongs to a group of medicines called antiretrovirals, used in the treatment of Human Immunodeficiency Virus (HIV-1) infection.
Maltese: Nevirapine Teva jappartjeni għal grupp ta' mediċini li jissejħu antiretrovirali, użati fit-trattament ta' infezzjonijiet ikkaġunati mill-Vajrus ta' Immunodefiċjenza Umana (HIV-1).
English: This study demonstrated a significant reduction in transmission using single dose nevirapine (13.1 % (n = 310) in the nevirapine group, versus 25.1 % (n = 308) in the ultra-short zidovudine group (p = 0.00063)).
Maltese: Dan l-istudju wera tnaqqis sinifikanti fit-trasmissjoni bl-użu ta' doża waħda ta' nevirapine (13.1% (n = 310) fil-grupp ta' nevirapine, kontra 25.
English: Cmax ↑ 1.47 (1.21-1.80) Nevirapine AUC ↑ 1.26
Maltese: Cmax ↑ 1.47 (1.21-1.80) għal metabolit 14-OH clarithromycin Nevirapine AUC ↑ 1.26
English: In clinical studies, nevirapine has been associated with an increase in HDL- cholesterol and an overall improvement in the total to HDL-cholesterol ratio.
Maltese: Fi studji kliniċi, nevirapine ġie assoċjat ma' żieda fl-HDL kolesterol u titjib globali fil-proporzjon talkolesterol totali mal-HDL kolesterol.
English: EE AUC ↓ 0.80 (0.67 - 0.97)
Maltese: EE AUC ↓ 0.80 (0.67 - 0.97) EE Cmin ND
English: Results of a 48-week analysis of the South African study BI 1100.1368 confirmed that the 4/7 mg/kg and 150 mg/m2 nevirapine dose groups were well tolerated and effective in treating antiretroviral naive paediatric patients.
Maltese: 1368 tal-Amerika t'Isfel ikkonferma li d-dożi ta' 4/7 mg/kg u 150 mg/m2 kienu ttollerati tajjeb u effettivi sabiex jiġu kkurati pazjenti antiretrovirali pedjatriċi inkonsaapevoli.
English: There are toxicities that require interruption of Nevirapine Teva therapy (see section 4.4).
Maltese: Hemm tossiċitajiet li jeħtieġu l-interruzzjoni ta' terapija b'Nevirapine Teva (ara sezzjoni 4.4).
English: The proportion of patients with at least one grade 3 or 4 liver-associated laboratory toxicity was 8.3% for nevirapine twice daily and 4.5% for efavirenz.
Maltese: Il-proporzjon ta' pazjenti b'tal-anqas tossiċità waħda tal-laboratorju ta' grad 3 jew 4 assoċjata mal-fwied kien ta' 8.3% għal nevirapine li ngħata darbtejn kuljum u 4.5% għal efavirenz.
English: Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma from approximately 45 hours (single dose) to approximately 25-30 hours following multiple dosing with 200-400 mg/day.
Maltese: Minħabba din l-eliminazzjoni jkun hemm tnaqqis bl- istess mod fl-aħħar fażi ta' half-life ta' nevirapine fil-plażma, minn madwar 45 siegħa (doża waħda) sa madwar 25-30 siegħa wara dożi multipli ta' 200-400 mg/jum.
English: Amprenavir Cmin ↓ 0.81 (0.69-0.96) Amprenavir Cmax ↔ 0.97 (0.85-1.10)
Maltese: Amprenavir AUC ↔ 0.89 (0.77-1.03) Amprenavir Cmin ↓ 0.81 (0.69-0.96) Amprenavir Cmax ↔ 0.97 (0.85-1.10)
English: The limited data available from a phase IIa study in HIV-infected patients have shown a clinically non significant 20% decrease of TPV
Maltese: IIa f'pazjenti infettati bl-HIV wera tnaqqis mhux klinikament sinifikanti ta' 20% fisCmin ta' TPV.
English: NET AUC ↓ 0.81 (0.70 - 0.93)
Maltese: NET AUC ↓ 0.81 (0.70 - 0.93) NET Cmin ND
English: How to take Nevirapine Teva
Maltese: Tieħux Nevirapine Teva
English: Nevirapine Cmin ↓ 0.32
Maltese: Nevirapine Cmax ↓ 0.50
English: It is not recommended to coadminister boceprevir and Nevirapine Teva (see section 4.4).
Maltese: Mhuwiex rakkomandat li tagħti flimkien boceprevir u Nevirapine Teva (ara sezzjoni 4.4).
English: Other medicines and Nevirapine Teva
Maltese: Mediċini oħra u Nevirapine Teva
English: Since neither body weight nor Body Mass Index (BMI) had influence on the clearance of nevirapine, the effect of gender cannot be explained by body size.
Maltese: Peress li la l-piż tal-ġisem u lanqas il-Body Mass Index (BMI) ma kellhom influwenza fuq ir-rata tal-eliminazzjoni ta' nevirapine, l-effett tas-sess tal-persuna ma jistax jiġi spjegat bid-daqs tal-ġisem.
English: Nevirapine Teva is indicated for the treatment of HIV-1 infected adults, adolescents, and children of any age.
Maltese: Nevirapine Teva hu indikat għall-kura ta' adulti, adolexxenti, u tfal ta' kull età infettati bl-HIV-1.
English: Renal impairment (mild, moderate and severe) resulted in no significant change in the pharmacokinetics of nevirapine.
Maltese: Indeboliment (ħafif, moderat, u qawwi) ma rriżulta fl-ebda bidla sinifikanti fil-farmakokinetika ta' nevirapine.
English: Didanosine Cmin ND Didanosine Cmax ↔ 0.98 (0.79-1.21)
Maltese: Didanosine AUC ↔ 1.08 (0.92-1.27) Didanosine Cmin ND Didanosine Cmax ↔ 0.98 (0.79-1.21)
English: Skin and subcutaneous tissue disorders
Maltese: Disturbi muskolu-skeletrali u tat-tessuti konnettivi
English: Plasma trough concentrations of boceprevir were decreased when administered with an NNRTI with a similar metabolic pathway as nevirapine.
Maltese: L-inqas livelli tal-konċentrazzjonijiet fil-plażma ta' boceprevir tnaqqsu meta ngħataw ma' NNRTI b'passaġġ metaboliku simili bħal nevirapine.
English: Stavudine Cmin ND Stavudine Cmax ↔ 0.94 (0.86-1.03)
Maltese: Stavudine AUC ↔ 0.96 (0.89-1.03) Stavudine Cmin ND Stavudine Cmax ↔ 0.94 (0.86-1.03)
English: Long-term efficacy appears to be most likely in patients whose nevirapine trough levels exceed 3.5 μg/ml.
Maltese: Effikaċja fit-tul tidher aktar f'pazjenti li l-anqas livelli ta' nevirapine huma aktar minn 3.5 µg/ml.
English: The overall incidence of adverse events was significantly lower (61 patients, or 41%) in the abacavir group than in the nevirapine group (83 patients, or 54%) or the efavirenz group (89 patients, or 57%).
Maltese: abacavir milli fil-grupp ta' nevirapine (83 pazjent, jew 54%) jew fil-grupp ta' efavirenz (89 pazjent,
English: Excipient with known effect: Each tablet contains 168 mg of lactose (as monohydrate).
Maltese: Kull pillola fiha 168 mg ta' lactose monohydrate.
English: Lopinavir Cmin ↓ 0.45 (0.25-0.82) Lopinavir Cmax ↓ 0.86 (0.64-1.16)
Maltese: Lopinavir AUC ↓ 0.78 (0.56-1.09) Lopinavir Cmin ↓ 0.45 (0.25-0.82) Lopinavir Cmax ↓ 0.86 (0.64-1.16)
English: Rifampicin Cmin ND Rifampicin Cmax ↔ 1.06 (0.91-1.22)
Maltese: Rifampicin AUC ↔ 1.11 (0.96-1.28) Rifampicin Cmin ND Rifampicin Cmax ↔ 1.06 (0.91-1.22)
English: NET Cmin ND
Maltese: Studju NEFA
English: Methadone Cmin ND Methadone Cmax ↓ 0.58 (0.50 - 0.67)
Maltese: Methadone AUC ↓ 0.40 (0.31 - 0.51) Methadone Cmin ND Methadone Cmax ↓ 0.58 (0.50 - 0.67)
English: How to store Nevirapine Teva Contents of the pack and other information
Maltese: Kontenut tal-pakkett u informazzjoni oħra
English: Of the patients with grade 3 or 4 liver-associated laboratory toxicity, the proportions coinfected with hepatitis B or hepatitis C virus were 6.7% and 20.0% in the nevirapine twice daily group, 5.6% and 11.1% in the efavirenz group.
Maltese: nevirapine li ngħata darbtejn kuljum, 5.6% u 11.1% fil-grupp ta' efavirenz.
English: Ketoconazole Cmax ↓ 0.56 (0.42
Maltese: Itraconazole Cmax ↓ 0.62
English: Nevirapine AUC ↓ 0.42
Maltese: Nevirapine AUC ↓ 0.42 Nevirapine Cmin ↓ 0.
English: Following intravenous administration to healthy adults, the volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 l/kg, suggesting that nevirapine is widely distributed in humans.
Maltese: Wara injezzjoni ġol-vina f'adulti b'saħħithom, il-volum ta' distribuzzjoni (Vdss) ta' nevirapine kien ta' 1.21 ± 0.09 l/kg.
English: Nevirapine Cmin ↑ 1.47 (1.20-1.82) Nevirapine Cmax ↑ 1.18 (1.02-1.37)
Maltese: Nevirapine AUC ↑ 1.27 (1.12-1.44) Nevirapine Cmin ↑ 1.47 (1.20-1.82) Nevirapine Cmax ↑ 1.18 (1.02-1.37)
English: Alternatives to clarithromycin, such as azithromycin should be considered.
Maltese: Alternattivi għal clarithromycin, bħal azithromycin għandhom jiġu kkunsidrati.
English: Nevirapine levels may increase on stopping St John‘s Wort.
Maltese: Il-livelli ta' nevirapine jistgħu jiżdiedu malli St John's Wort jitwaqqaf.
English: Cmin.
Maltese: ULN.
English: The first 18 weeks of treatment is a critical period which requires close monitoring.
Maltese: L-ewwel 18-il ġimgħa ta' kura huwa perijodu kritiku li jeħtieġ monitoraġġ mill qrib.
English: Ketoconazole Cmin ND
Maltese: Mhux irrakkomandat li ketoconazole u
English: Lopinavir Cmin ↓ 0.54 (0.28-0.74) Lopinavir Cmax ↓ 0.81 (0.62-0.95)
Maltese: Lopinavir AUC ↓ 0.73 (0.53-0.98) Lopinavir Cmin ↓ 0.54 (0.28-0.74) Lopinavir Cmax ↓ 0.81 (0.62-0.95)
English: By stopping reverse transcriptase from working, Nevirapine Teva helps control HIV-1 infection.
Maltese: Meta jwaqqaf reverse transcriptase milli jaħdem, Nevirapine Teva jgħin biex jikkontrolla l-infezzjoni ta' HIV-1.
English: Due to the metabolic pathway no clinically significant pharmacokinetic interactions are expected between enfuvirtide and nevirapine.
Maltese: Minħabba l-passaġġ metaboliku mhux mistenni li jkun hemm interazzjonijiet farmakokinetiċi klinikament sinifikanti bejn enfuvirtide u nevirapine.
English: The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing (see section 5.1).
Maltese: L-għażla ta' terapija sussegwenti wara nevirapine għandha tkun ibbażata fuq esperjenza klinika u testijiet ta' reżistenza (ara sezzjoni 5.1)
English: Changes of body fat may occur in patients receiving combination antiretroviral therapy.
Maltese: anormalitajiet fil-fwied meta jingħataw terapija antiretrovirali kkombinata.
English: At 12 months, the Kaplan-Meier estimates of the likelihood of reaching the endpoint were 10 % in the nevirapine group, 6 % in the efavirenz group, and 13 percent in the abacavir group (P=0.10 according to an intention-to-treat analysis).
Maltese: Wara 12-il xahar l-istimi ta' Kaplan-Meier dwar il-probabilità sabiex jintlaħaq il-punt ta' riferiment aħħari kienu ta' 10% għal grupp ta' nevirapine, 6% għal grupp ta' efavirenz, u 13% fil-grupp ta' abacavir (P=0.10 skont l-analiżi għal ħsieb ta' kura).
English: Hepatic impairment
Maltese: Riżultati kliniċi